David Smadja/Wikipedia
Jun 7, 2025, 08:46
David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
David Smadja, Team Director “Endotheliopathy and hemostasis disorders” at INSERM The Paris Cardiovascular Research Center, shared a post on LinkedIn:
“A major step forward in the fight against cancer-related thrombosis!
In the journal VAINCRE LE CANCER – NRB, we take a look back at the API-CAT study, led by Prof. Isabelle Mahé (Louis Mourier Hospital AP-HP) and our team at PARCC – Inserm Endotheliopathy & Hemostasis Disorders.
Result? A reduced dose of apixaban is sufficient to prevent thromboembolic recurrence with less bleeding.
This is further proof that academic research is changing clinical practices. Proud to contribute to this breakthrough in the service of cancer patients.”
You can read a wide variety of new scientific posts in Hemostasis Today.
-
Apr 10, 2026, 18:22Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
-
Apr 10, 2026, 17:59Michelle Leona Cecil: Representing Microhealth at The Coalition for Hemophilia B Annual Symposium
-
Apr 10, 2026, 17:47Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
-
Apr 10, 2026, 17:39Diverse Voices But Shared Mission – Day 1 of EHC Youth Leadership Workshop
-
Apr 10, 2026, 17:30Make Your Mark at the World Stroke Congress 2026 – World Stroke Organization
-
Apr 10, 2026, 17:23Sofie Abels: Implications for Targeted Screening for Thrombophilia in Young Stroke Patients
-
Apr 10, 2026, 17:08Armghan Ans: 3 Questions Worth Sitting with If You Work in Stroke AI
-
Apr 10, 2026, 17:03William Wallace: Vitamin C Is More Than ”Immune Support”
-
Apr 10, 2026, 16:58Wolfgang Miesbach: Greater Symptom Burden in Women with Bleeding Disorders – Insights from Irish Data